Japanese researchers claimed that the DNA-based vaccine they are developing have successfully neutralized SARS-CoV-2.
Researchers from the Osaka University in Osaka, Japan used two methodologies in the study: the pseudovirus assay as well as the binding assay, which involves Receptor Binding Domain recombinant protein (RBD) with angiotensin-converting-enzyme 2 (ACE2).
Pre-clinical trial's initial results show that the immunogenicity of the DNA vaccine, which target on S-protein can be used as basis to evidence, so researchers can proceed with clinical trials. They believe DNA-based vaccines against COVID-19 may alleviate the current health crisis that continues to ravage the world.
As of this writing, there are about 41.7 million confirmed COVID-19 cases across the globe with at least 1.14 million deaths. In the U.S., there are already 8.46 million cases and at least 223,000 deaths reported.
The vaccine's future Phase 3 trial in the U.S.
On October 22, Hilda Bastian, a health advocate and scientists shared in Twitter that the DNA vaccine being developed by Osaka University may be soon undergo Phase 3 trial in the U.S. She pointed out signs of such possibility.
These include the publication of the preprint and the announcement of AnGes, the partner company of Osaka University in developing this COVID-19 vaccine, in Sept that it had a deal to collaborate with a U.S. company Brickell Biotech, Inc. in preparation for Phase 3 trials once the phase 1/2 goes well. Also, AnGes projected that the vaccine will get into the market by 2021.
Related article: [Fact Check] Did the Astrazeneca-Oxford Vaccine Cause a Brazilian Doctor Volunteer to Die?
This is owned by Tech Times
Written by CJ Robles